BioSpace News Archive

Apotex Corp is voluntarily recalling two (2) batches of Enoxaparin Sodium Injection, USP to consumer level due to a packaging error resulting in some syringes barrels containing 150 mg/mL markings (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength) on the syringe barrel and vice versa.

Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Shao-Lee Lin, M.D., Ph.D. to the Board of Directors.

As healthcare providers across Arkansas continue to meet the needs of patients impacted by COVID-19 or requiring surgery, state legislators are considering bills that will affect patients’ access to affordable care.

Ulbrich understands the need for rapid Medical Device development cycles. With the new Ulbrich Braid Wire Accelerator™ Program, timelines and specific design performance characteristics are faster and more precise than ever before.

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that based on a notification letter recently received from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”), the Company has regained compliance with the minimum bid price requirement set forth

Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally well-tolerated and has shown a safety profile comparable to irbesartan

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has secured a commitment of up to C$14 million (US$ 11 million) from the Government of Canada to complete the Phase 2 portion of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients.

Starting Thursday, February 11, CVS Health will begin to offer COVID-19 vaccinations to eligible populations at a limited number of CVS Pharmacy locations across 11 states.

Connecticut is among an initial 11 state rollout and part of the company’s larger plan to expand access to COVID-19 vaccines at CVS Pharmacy locations across the country

California is among an initial 11 state rollout and part of the company’s larger plan to expand access to COVID-19 vaccines at CVS Pharmacy locations across the country